New Study Shows 94% Reduction in COVID-19 Cases in a Residential Healthcare Facility With ActivePure Technology

DALLAS, April 17, 2024 (Newswire.com) - Today, ActivePure Technologies, LLC released key findings from a seminal study conducted inside a long-term care facility, which demonstrated the technology’s efficacy in safeguarding long-term care residents from infection risks, specifically from the respiratory pathogen Sars-CoV-2.

The COVID-19 pandemic highlighted the vulnerabilities inside long-term care facilities, where outbreaks disproportionately devastated residents and staff. While the initial crisis from the pandemic may have passed, significant gaps in care persist, including inadequate staffing, lax infection control protocols and a lack of capital resources, which places many long-term care facilities at high risk for future outbreaks and rising costs of care from preventable infections. 

But as the industry works to rebuild its human capital resources, including the worker pipeline of infection control specialists and licensed practical nurses, long-term care facilities must embrace environmental technologies that can improve their standard of care and reduce infection risks without increasing labor demands.  

To address this need, ActivePure, a leader in surface and air decontamination systems, worked alongside a leading provider in long-term care in its latest study to evaluate its patented technology’s ability to decrease risk from pathogen spread indoors. The study focused on the respiratory pathogen SARS-CoV-2, the virus that causes COVID-19, as such infections can increase the risk of heart attack and stroke by directly infecting the arteries of the heart, according to findings from a recent study funded by the National Institutes of Health.  

ActivePure conducted a clinical study inside a skilled nursing facility from January to April 2023 with an extended observation period, analyzing the impacts of ActivePure Technology on preventing COVID-19 infection rates among residents. The study design utilized one center as the intervention arm and two matched control centers in regional proximity to the intervention facility. At the end of the extended observation period, which ran from February – July, the ActivePure intervention facility observed:

• A 94% reduction in resident COVID-19 cases compared to the prior year
• The matched control facilities experienced an average increase of 46% compared to the prior year

There were .64 cases/1000 resident days in the intervention facility and an average of 14.09 cases/1000 resident days in the control facilities over those six months. 

The full study results will be presented at the Society for Healthcare Epidemiology of America (SHEA) Spring Conference 2024, taking place April 16-19 in Houston, by ActivePure co-authors Amy Carenza, chief commercial officer and Kim Trosch, director of clinical affairs.

In both laboratory studies and real-world settings, ActivePure Technology continues to prove its efficacy against a broad range of pathogens, including virulent Bacillus globigii spores and lower-resistance pathogens like SARS-CoV-2. Unaffiliated testing confirms that ActivePure Technology can rapidly deactivate over 99.9% of highly concentrated airborne SARS-CoV-2 virus in just 60 seconds, reducing it to undetectable levels. 

For more information on ActivePure and long-term care facilities, visit ActivePure.com.

Source: ActivePure Technologies, LLC